Revance Files $86.25 Million IPO

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Revance Therapeutics, Inc. (Nasdaq: RVNC) filed a registration with the U.S. Securities and Exchange Commission for an Initial Public Offering of its Common Stock. The proposed maximum offering price is $86.25 million. The company plans to list on the Nasdaq Global Market under the symbol "RVNC."

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC